RxDoctor Payments Data

Randall Meisner, MD

Gastroenterology · Grand Rapids, MINPI 1003869215

Payments from drug & device makers

$10,423in general payments, 2019–2025

Across 79 payments — averaging $131.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$8K
  • Boston Scientific$825
  • ERBE USA Inc$735
  • Johnson & Johnson$209
  • AbbVie$193
  • Apollo Endosurgery US Inc$112
  • plus $262 from 6 others

What the payments were for

  • Consulting fees$4,70045%
  • Food & beverage$5,61854%
  • Education$300%
  • Entertainment$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,423 in reported general payments places this provider in the 75th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$61,766
Medicare patients
255
Services billed
576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$448,973
Skyrizi On-BodyRisankizumab-Rzaa14$279,892
Humira(Cf) PenAdalimumab17$203,058
Humira PenAdalimumab13$86,090
Balsalazide Disodium95$30,980
LinzessLinaclotide27$20,597
VemlidyTenofovir Alafenamide11$14,431
Mesalamine37$13,985
Mesalamine ErMesalamine20$10,929
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg366$9,119
SutabSod Sulf/Pot Chloride/Mag Sulf41$6,556
Omeprazole346$5,949
Opium Tincture12$4,338
Pantoprazole Sodium258$3,710
Budesonide DrBudesonide38$2,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$209$448,97317 claims
AbbVieLinzess$193$20,59727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →